🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07294027
Starting soon Not applicable

ICSI Versus Conventional IVF in Couples With Unexplained Infertility

NCT07294027 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2026-01-01
Last updated
2025-12-19

Condition(s) studied

Unexplained Infertility

Investigational drug(s) / intervention(s)

ICSIIVF

ICSI: Insemination will be performed by using ICSI, 2 hours after oocyte retrieval. COCs will be stripped by using hyaluronidase. Only matured oocytes (MII stage) will be injected. Fertilization check will be performed at period of 16-18 hours after injection. Other standard assisted reproductive treatments are similar and parallel between two groups.

IVF: Insemination will be performed by using conventional IVF, 2-4 hours after oocyte retrieval. Collected COCs will be inseminated (1-5×105 sperm/ml) and cultured overnight in culture medium. Fertilization check will be performed at period of 16-18 hours after insemination. If the IVF group experiences total fertilization failure or a fertilization rate of less than 25%, late rescue ICSI (Late-RICSI) will be performed on all MII stage oocytes using semen retained on the day of egg retrieval. The injection method is same as standard ICSI. Other standard assisted reproductive treatments are similar and parallel between two groups.

Study summary

This multicenter, open-label, parallel-group, randomized controlled trial aims to compare the live birth rate, fertilization outcomes, other pregnancy outcomes and safety between ICSI and conventional IVF among couples with unexplained infertility in China.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
38 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 20-38 years 2. 18.5 \< BMI \< 24kg/m2 3. Couples diagnosed with primary unexplained infertility: * Regular menses or confirmed ovulation; * Normal ovarian reserve; * Patent fallopian tubes; * Normal uterus and cervix; * Normal endocrine profile; * Semen analysis meeting WHO 6th edition criteria * Normal karyotypes in both partners, no family history of genetic disorders 4. First IVF/ICSI cycle 5. Received GnRH agonist protocol or GnRH antagonist protocol 6. Willing to provide informed consent and comply with follow-up Exclusion Criteria: 1. Preimplantation genetic testing (PGT) cycles 2. In vitro maturation (IVM) cycles 3. Using donor sperm/oocyte 4. Using frozen sperm/oocyte 5. \<5 oocytes retrieved 6. Abnormal semen parameters on the day of oocyte retrieval 7. High risk of tubal pathology or endometriosis without laparoscopic exclusion 8. Untreated or poorly controlled endocrine disorders 9. Abnormal immune related examinations 10. Major organ/system disorders (cardiac, hepatic, renal, oncologic, hematologic, psychiatric, etc.) 11. Concurrent participation in other clinical trials.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Beijing Obstetrics and Gynecology Hospital, Capital Medical University Beijing Beijing Municipality
Huangshi Central Hospital Huangshi Hubei
Renmin Hospital of Wuhan University Wuhan Hubei
Xiangyang Central Hospital Xiangyang Hubei
Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang
Jiaxing Maternity and Child Health Care Hospital Jiaxing Zhejiang
Ningbo Women & Children's Hospital Ningbo Zhejiang

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07294027 on ClinicalTrials.gov ↗ ← All trials in China